Retained by a Class Action Settlement Claim Processing Provider

Vega calculated the total EpiPen sales to end payers eligible for settlement claims in In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation (2:17‐md‐02785). 

Symphony Health Solutions reports prescription drugs dispensed from retail and institutional channels.  We analyzed the Total Prescription Manufacturer's Benchmark Sales Dollars for Epinephrine Auto or Pen Injectors. This metric measures the projected total sales for total prescriptions dispensed based on the manufacturer's published list prices. 

By this metric, we calculated the total sales between August 24, 2011 and November 1, 2020 (RICO Class Period) and total sales between January 28, 2013 and November 1, 2020 (State Antitrust Class Period). 

This data source available to Vega Economics contains historical prices by manufacturers, sales by distribution channels, as well as statistics on drug licensing deals for a wide range of brand-name, generic, and specialties pharmaceutical drugs.

For additional information, please email